LENZ Therapeutics, Inc. (LENZ) Wednesday announced positive results from the Phase 3 CLARITY study of its two drug candidates LNZ100 and LNZ101, for the treatment of presbyopia, the loss of eye's ability to see nearby objects. The company's shares were up more than 20 percent in pre-market at $26.10.In the Phase 3 CLARITY 1 and 2 trials, the primary endpoint was met after 71 percent of participants dosed with LNZ100 achieved three-lines or greater improvement at 3 hours.

LENZ Therapeutics，Inc.（LENZ）周三宣布，其两种候选药物LNZ100和LNZ101的第三阶段清晰度研究取得了积极结果，用于治疗老视，即眼睛看不见附近物体的能力丧失。该公司股价在上市前上涨了20%以上，达到26.10美元。在第三阶段CLARITY 1和2试验中，71%服用LNZ100的参与者在3小时内达到了三条线或更大的改善，达到了主要终点。

The company has chosen LNZ100 as its lead drug candidate. While LNZ101 also showed similar results, it was not superior to LNZ100..

该公司已选择LNZ100作为其主要候选药物。虽然LNZ101也显示出类似的结果，但它并不优于LNZ100。。

LENZ Therapeutics plans to submit a New Drug Application for LNZ100 in mid-2024.Shares of LENZ Therapeutics had closed at $21.01 on Tuesday. The stock has been trading in the range of $2.01 - $24.05 in the last 52 weeks. For comments and feedback contact: editorial@rttnews.comBusiness News

LENZ Therapeutics计划在2024年年中提交LNZ100的新药申请。LENZ Therapeutics的股价周二收于21.01美元。该股在过去52周的交易价格在2.01美元至24.05美元之间。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

使用RTT Intelligent Investor访问溢价股票警报。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股